마취 및 호흡 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2025-2030년)

Anesthesia And Respiratory Devices Market Size, Share & Trends Analysis Report By Product (Respiratory Devices (), Anesthesia Devices), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

마취 및 호흡 기기 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 마취 및 호흡 기기 시장 규모는 2025년부터 2030년까지 5.9%의 CAGR을 기록하여 2030년에는 759억 달러에 달할 것으로 예상됩니다.

호흡기질환의 유병률 증가, 입원 기간 단축을 원하는 환자들의 선호도, 정부의 재정 지원 등이 주요 촉진요인입니다. 또한 고령화는 수면무호흡증 발병의 가장 큰 위험 요소 중 하나로 간주되어 이 산업에 큰 영향을 미치는 렌더링 촉진요인이 될 것으로 예상되며, COVID-19 사태는 업계에 큰 영향을 미쳤습니다. 부문에 따라 그 영향은 다릅니다. 예를 들어, 인공호흡기 분야는 기계식 인공호흡기 수요의 급격한 증가로 인해 급격한 성장을 보였습니다.

그러나 이 수요는 2021년 이후 감소하여 산업 규모가 급격히 축소되었습니다. 분무기 분야는 바이러스 감염과 면역 억제의 잠재적 원인으로 여겨지는 흡입제 사용으로 인해 사람들은 분무기 사용에 대한 불안감을 가지고 있었습니다. 환자의 선호도가 입원 기간 단축으로 이동함에 따라 마취 및 호흡 기기 기계 채택이 증가하여 시장을 주도할 것으로 예상됩니다. 미국 병원협회에 따르면, 메디케어 수혜자의 약 20%가 퇴원 후 30일 이내에 재입원하는 것으로 나타났습니다. 피할 수 있는 재입원을 식별하고 줄이는 것은 의료 안전성을 향상시키고 지출을 줄일 수 있을 것으로 기대됩니다.

이 때문에 정책 입안자들은 환자의 재입원 일수를 줄이기 위해 노력하고 있습니다. 의회는 2013년부터 환자보호 및 의료비 적정화법(Patient Protection and Affordable Act)을 통해 병원 재입원 감소 프로그램(Hospital Readmission Reduction Program, HRRP)을 시작했으며, 이에 따라 메디케어(Medicare)는 재입원율이 높은 병원에 대해 페널티를 부과할 수 있게 되었습니다. 이 법의 시행으로 많은 의사와 환자들이 외래용 수액 펌프와 가정용 호흡 모니터와 같은 마취 및 호흡 장비를 선택하고 있습니다. 주요 업체들은 치료를 개선하기 위해 첨단 장비를 개발하기 위한 노력을 기울이고 있습니다. 예를 들어, 2022년 5월 맥스 벤틸레이터(Max Ventilator)는 가습기와 산소 요법이 내장된 비침습적(NIV) 인공호흡기를 출시했습니다. 이 기기는 사용하기 쉽고 가볍고 기존 인공호흡기보다 가격이 저렴합니다. 이러한 노력은 향후 몇 년 동안 업계의 성장을 촉진할 것으로 예상됩니다.

마취 및 호흡 기기 시장 보고서 하이라이트:

• 수익 측면에서는 만성폐쇄성폐질환(COPD), 천식, 결핵 등의 유병률 증가로 인해 호흡기 기기 분야가 2024년 가장 큰 매출 점유율을 차지했습니다.
• 마취 장비 분야는 수술 건수 증가와 시장 진입 기업들의 다양한 기술 발전으로 인해 예측 기간 동안 크게 성장할 것으로 예상됩니다.
• 북미는 2024년 주요 기업의 존재로 인해 가장 큰 매출 점유율을 차지했습니다.
• 아시아태평양은 헬스케어 지출 증가와 환자 인식 증가로 인해 예측 기간 동안 가장 빠른 CAGR을 보일 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 마취 및 호흡 기기 시장 변수, 동향, 범위

• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회
• 마취 및 호흡 기기 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 마취 및 호흡 기기 시장 : 제품 추정·동향 분석

• 제품 유형 시장 점유율, 2023년 및 2030년
• 부문 대시보드
• 제품 유형별
  • 마취 기기
  • 호흡 기기

제5장 마취 및 호흡 기기 시장 : 지역 추정·동향 분석, 제품별

• 지역별 시장 점유율 분석, 2023년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제6장 경쟁 상황

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 주요 기업의 시장 점유율/포지션 분석, 2023년
• 기업 개요
  • General Electric Company
  • Medtronic
  • Teleflex Incorporated
  • Koninklijke Philips NV
  • Dragerwerk AG &CO. KGAA
  • Getinge AB
  • Smiths Group PLC
  • Fisher &Paykel Healthcare Limited
  • Masimo
  • Braun Melsungen AG
  • ResMed
  • Inogen, Inc.
  • Caire Medical(a subsidiary of NGK Spark Plug)
  • DeVilbiss Healthcare(a subsidiary of Drive Medical)
  • React Health(Respiratory Product Line from Invacare Corporation)
  • O2 Concepts
  • Nidek Medical Products, Inc.
  • Omron Corporation
  • GE Healthcare
  • Allied Healthcare
  • Vectura Group Plc.
  • PARI Respiratory Equipment, Inc.
  • Aerogen
  • DeVilbiss Healthcare LLC
  • Briggs Healthcare
  • Beurer GmBH

ksm

영문 목차

영문목차

Anesthesia And Respiratory Devices Market Growth & Trends:

The global anesthesia and respiratory devices market size is estimated to reach USD 75.9 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of respiratory diseases, patient preferences for a reduced hospital stay and supportive government funding are among the key driving factors. Furthermore, aging is considered one of the greatest risk factors for the development of sleep apnea disorders and is, therefore, expected to be a high-impact rendering driver for this industry. The COVID-19 pandemic had a significant impact on the industry. Different segments were impacted differently. For instance, the ventilators segment witnessed exponential growth owing to the sudden surge in the demand for mechanical ventilators.

However, this demand decreased post-2021, wherein the industry size decreased dramatically. Concerning the nebulizers segment, people were apprehensive to use nebulizers owing to the use of inhaled medications, which are considered a potential source of viral transmission and immunosuppression, which restricted the growth, but did not negatively impact the industry. Shifting the preference of patients towards reduced hospital stay is anticipated to increase the adoption of anesthesia and breathing instruments, thereby, driving the market. As per the American Hospital Association, approximately 20% of Medicare beneficiaries, when discharged from the hospital return within 30 days. Identifying and reducing avoidable readmissions is expected to improve healthcare safety and reduce spending.

Hence, policymakers are striving to reduce the hospital stays of patients. In the Patient Protection and Affordable Act, Congress initiated the Hospital Readmission Reduction Program (HRRP), under which, Medicare is allowed to penalize hospitals for higher rates of readmissions since 2013. Due to the implementation of this act, many physicians and patients opt for anesthesia and breathing devices, such as ambulatory infusion pumps and home respiratory monitors. Key players are taking initiatives to develop advanced instruments to bring improvement in the treatment. For instance, in May 2022, Max Ventilator launched Non-Invasive (NIV) ventilators consisting of inbuilt humidifiers and oxygen therapy. The device is user-friendly as well as lightweight and is also priced lower than the traditional ventilators. Such initiatives are anticipated to propel industry growth in the coming years.

Anesthesia And Respiratory Devices Market Report Highlights:

• In terms of revenue, the respiratory devices segment held the largest revenue share in 2024, owing to the rising prevalence of Chronic Obstructive Pulmonary Disease (COPD), asthma, and tuberculosis, among others
• The anesthesia devices segment is expected to grow significantly over the forecast period, owing to the rising number of surgeries and various technological advancements by market players
• North America accounted for the largest revenue share in 2024 owing to the presence of major players in the region
• Asia Pacific is expected to witness the fastest CAGR during the forecast period owing to increasing healthcare expenditure and awareness among patients.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product outlook
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anesthesia and Respiratory Devices Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market Opportunities
• 3.2. Anesthesia and Respiratory Devices Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. COVID-19 Impact Analysis

Chapter 4. Anesthesia and Respiratory Devices Market: Product Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Brain Computer Interface Market by Product Type Outlook
  • 4.3.1. Anesthesia Devices
    • 4.3.1.1. Anesthesia Devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1. Anesthesia Machines
        • 4.3.1.1.1.1. Anesthesia Machines market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.2. Anesthesia Workstation
          • 4.3.1.1.1.2.1. Anesthesia Workstation market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.3. Anesthesia Delivery Station
          • 4.3.1.1.1.3.1. Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.3.2. Portable Anesthesia Delivery Station
    • 4.3.1.1.1.3.2.1. Portable Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.3.3. Standalone Anesthesia Delivery Station
    • 4.3.1.1.1.3.3.1. Standalone Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.4. Anesthesia Ventilators
        • 4.3.1.1.1.4.1. Anesthesia Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.5. Anesthesia Monitors
        • 4.3.1.1.1.5.1. Anesthesia Monitors market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.2. Anesthesia Disposables
        • 4.3.1.1.2.1. Anesthesia Disposables market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.2.2. Anesthesia Masks
          • 4.3.1.1.2.2.1. Anesthesia Masks market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.2.3. Anesthesia Accessories
          • 4.3.1.1.2.3.1. Anesthesia Accessories market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Respiratory Devices
    • 4.3.2.1. Respiratory devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1. Respiratory Equipment's
        • 4.3.2.1.1.1. Respiratory Equipment's market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.2. Humidifiers
          • 4.3.2.1.1.2.1. Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
          • 4.3.2.1.1.2.2. Heat Humidifiers
    • 4.3.2.1.1.2.2.1. Heat Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.3. Heated wire breathing circuits
    • 4.3.2.1.1.2.3.1. Heated wire breathing circuits market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.4. Heat Exchangers
    • 4.3.2.1.1.2.4.1. Heat Exchangers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.5. Pass Over Humidifiers
    • 4.3.2.1.1.2.5.1. Pass Over Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3. Nebulizers
        • 4.3.2.1.1.3.1. Nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.3.2. Pneumatic nebulizers
    • 4.3.2.1.1.3.2.1. Pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3.3. Mesh nebulizers
    • 4.3.2.1.1.3.3.1. Mesh nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3.4. Ultrasonic nebulizers
    • 4.3.2.1.1.3.4.1. Ultrasonic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.4. Oxygen Concentrators
        • 4.3.2.1.1.4.1. Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.4.2. Fixed Oxygen Concentrators
    • 4.3.2.1.1.4.2.1. Fixed Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.4.3. Portable Oxygen Concentrators
    • 4.3.2.1.1.4.3.1. Portable Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.5. Positive airway pressure devices
        • 4.3.2.1.1.5.1. Positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.5.2. Bi-level positive airway pressure devices
    • 4.3.2.1.1.5.2.1. Bi-level positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.5.3. Continuous positive airway pressure devices
    • 4.3.2.1.1.5.3.1. Continuous positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.6. Reusable resuscitators
        • 4.3.2.1.1.6.1. Reusable resuscitators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.7. Ventilators
        • 4.3.2.1.1.7.1. Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.7.2. Adult Ventilators
    • 4.3.2.1.1.7.2.1. Adult Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.7.3. Neonatal Ventilators
    • 4.3.2.1.1.7.3.1. Neonatal Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.8. Respiratory inhalers
        • 4.3.2.1.1.8.1. Respiratory inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.8.2. Dry Powdered Inhalers
    • 4.3.2.1.1.8.2.1. Dry Powdered Inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.8.3. Meter Dose Inhalers
    • 4.3.2.1.1.8.3.1. Meter Dose Inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9. Respiratory disposable
        • 4.3.2.1.1.9.1. Respiratory disposable market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.9.2. Disposable Oxygen Mask
    • 4.3.2.1.1.9.2.1. Disposable oxygen mask market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.3. Resuscitators
    • 4.3.2.1.1.9.3.1. Resuscitators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.4. Tracheostomy Tubes
    • 4.3.2.1.1.9.4.1. Tracheostomy Tubes market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.5. Oxygen Cannula
    • 4.3.2.1.1.9.5.1. Oxygen Cannula market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10. Respiratory measurement devices
        • 4.3.2.1.1.10.1. Respiratory measurement devices market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.10.2. Pulse oximetry systems
    • 4.3.2.1.1.10.2.1. Pulse oximetry systems market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.3. Capnographs
    • 4.3.2.1.1.10.3.1. Capnographs market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.4. Spirometers
    • 4.3.2.1.1.10.4.1. Spirometers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.5. Peak flowmeters
    • 4.3.2.1.1.10.5.1. Peak flowmeters market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anesthesia and Respiratory Devices Market: Regional Estimates & Trend Analysis, By Product

• 5.1. Regional Market Share Analysis, 2023 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Global Regional Market Snapshot
• 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.5. North America
  • 5.5.1. U.S.
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Canada
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Mexico
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Europe
  • 5.6.1. UK
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Germany
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. France
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Italy
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework/ reimbursement structure
    • 5.6.4.3. Competitive scenario
    • 5.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Spain
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework/ reimbursement structure
    • 5.6.5.3. Competitive scenario
    • 5.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Norway
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework/ reimbursement structure
    • 5.6.6.3. Competitive scenario
    • 5.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.7. Sweden
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Regulatory framework/ reimbursement structure
    • 5.6.7.3. Competitive scenario
    • 5.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.8. Denmark
    • 5.6.8.1. Key country dynamics
    • 5.6.8.2. Regulatory framework/ reimbursement structure
    • 5.6.8.3. Competitive scenario
    • 5.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Asia Pacific
  • 5.7.1. Japan
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. China
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. India
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Australia
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.5. South Korea
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.6. Thailand
    • 5.7.6.1. Key country dynamics
    • 5.7.6.2. Regulatory framework/ reimbursement structure
    • 5.7.6.3. Competitive scenario
    • 5.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Latin America
  • 5.8.1. Brazil
    • 5.8.1.1. Key country dynamics
    • 5.8.1.2. Regulatory framework/ reimbursement structure
    • 5.8.1.3. Competitive scenario
    • 5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Argentina
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework/ reimbursement structure
    • 5.8.2.3. Competitive scenario
    • 5.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. MEA
  • 5.9.1. South Africa
    • 5.9.1.1. Key country dynamics
    • 5.9.1.2. Regulatory framework/ reimbursement structure
    • 5.9.1.3. Competitive scenario
    • 5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. Saudi Arabia
    • 5.9.2.1. Key country dynamics
    • 5.9.2.2. Regulatory framework/ reimbursement structure
    • 5.9.2.3. Competitive scenario
    • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. UAE
    • 5.9.3.1. Key country dynamics
    • 5.9.3.2. Regulatory framework/ reimbursement structure
    • 5.9.3.3. Competitive scenario
    • 5.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.4. Kuwait
    • 5.9.4.1. Key country dynamics
    • 5.9.4.2. Regulatory framework/ reimbursement structure
    • 5.9.4.3. Competitive scenario
    • 5.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Key company market share/position analysis, 2023
• 6.4. Company Profiles
  • 6.4.1. General Electric Company
    • 6.4.1.1. Company Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Medtronic
    • 6.4.2.1. Company Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Teleflex Incorporated
    • 6.4.3.1. Company Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Koninklijke Philips N.V.
    • 6.4.4.1. Company Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Dragerwerk AG & CO. KGAA
    • 6.4.5.1. Company Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Getinge AB
    • 6.4.6.1. Company Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Smiths Group PLC
    • 6.4.7.1. Company Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Fisher & Paykel Healthcare Limited
    • 6.4.8.1. Company Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Masimo
    • 6.4.9.1. Company Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Braun Melsungen AG
    • 6.4.10.1. Company Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic initiatives
  • 6.4.11. ResMed
    • 6.4.11.1. Company Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic initiatives
  • 6.4.12. Inogen, Inc.
    • 6.4.12.1. Company Overview
    • 6.4.12.2. Financial Performance
    • 6.4.12.3. Product Benchmarking
    • 6.4.12.4. Strategic initiatives
  • 6.4.13. Caire Medical (a subsidiary of NGK Spark Plug)
    • 6.4.13.1. Company Overview
    • 6.4.13.2. Financial Performance
    • 6.4.13.3. Product Benchmarking
    • 6.4.13.4. Strategic initiatives
  • 6.4.14. DeVilbiss Healthcare (a subsidiary of Drive Medical)
    • 6.4.14.1. Company Overview
    • 6.4.14.2. Financial Performance
    • 6.4.14.3. Product Benchmarking
    • 6.4.14.4. Strategic initiatives
  • 6.4.15. React Health (Respiratory Product Line from Invacare Corporation)
    • 6.4.15.1. Company Overview
    • 6.4.15.2. Financial Performance
    • 6.4.15.3. Product Benchmarking
    • 6.4.15.4. Strategic initiatives
  • 6.4.16. O2 Concepts
    • 6.4.16.1. Company Overview
    • 6.4.16.2. Financial Performance
    • 6.4.16.3. Product Benchmarking
    • 6.4.16.4. Strategic initiatives
  • 6.4.17. Nidek Medical Products, Inc.
    • 6.4.17.1. Company Overview
    • 6.4.17.2. Financial Performance
    • 6.4.17.3. Product Benchmarking
    • 6.4.17.4. Strategic initiatives
  • 6.4.18. Omron Corporation
    • 6.4.18.1. Company Overview
    • 6.4.18.2. Financial Performance
    • 6.4.18.3. Product Benchmarking
    • 6.4.18.4. Strategic initiatives
  • 6.4.19. GE Healthcare
    • 6.4.19.1. Company Overview
    • 6.4.19.2. Financial Performance
    • 6.4.19.3. Product Benchmarking
    • 6.4.19.4. Strategic initiatives
  • 6.4.20. Allied Healthcare
    • 6.4.20.1. Company Overview
    • 6.4.20.2. Financial Performance
    • 6.4.20.3. Product Benchmarking
    • 6.4.20.4. Strategic initiatives
  • 6.4.21. Vectura Group Plc.
    • 6.4.21.1. Company Overview
    • 6.4.21.2. Financial Performance
    • 6.4.21.3. Product Benchmarking
    • 6.4.21.4. Strategic initiatives
  • 6.4.22. PARI Respiratory Equipment, Inc.
    • 6.4.22.1. Company Overview
    • 6.4.22.2. Financial Performance
    • 6.4.22.3. Product Benchmarking
    • 6.4.22.4. Strategic initiatives
  • 6.4.23. Aerogen
    • 6.4.23.1. Company Overview
    • 6.4.23.2. Financial Performance
    • 6.4.23.3. Product Benchmarking
    • 6.4.23.4. Strategic initiatives
  • 6.4.24. DeVilbiss Healthcare LLC
    • 6.4.24.1. Company Overview
    • 6.4.24.2. Financial Performance
    • 6.4.24.3. Product Benchmarking
    • 6.4.24.4. Strategic initiatives
  • 6.4.25. Briggs Healthcare
    • 6.4.25.1. Company Overview
    • 6.4.25.2. Financial Performance
    • 6.4.25.3. Product Benchmarking
    • 6.4.25.4. Strategic initiatives
  • 6.4.26. Beurer GmBH
    • 6.4.26.1. Company Overview
    • 6.4.26.2. Financial Performance
    • 6.4.26.3. Product Benchmarking
    • 6.4.26.4. Strategic initiatives

관련자료